Keyword: Claire McCaskill
Democrats rolled out their new economic agenda Monday, calling it a “Better Deal.” For consumers, maybe. For the pharma industry, not so much.
Ohio’s attorney general is going after drugmakers for alleged “fraudulent marketing practices” on opioid painkillers.
The painkiller Ofirmev doubled in price after Mallinckrodt bought it—and it's the latest investigative target of Sen. Claire McCaskill. But this probe isn’t so cut-and-dried.
A top Senate Democrat is throwing the weight of her office behind efforts to dig into opioid marketing practices.
The power of a Hillary Clinton tweet showed again Wednesday, when the presidential candidate spoke on drug price, raising fears of government action. Biotech stocks, pharma stocks--even U.K. drugmakers suffered.
Amid a frenzy of criticism for the price of EpiPen, Mylan swiftly expanded its co-pay help for patients. But it did not adjust the actual price of a med that’s more than 400% more expensive than it was in 2009.
Valeant CEO Michael Pearson spent long hours under questioning in Washington, DC, on Monday as a Senate committee continued its probe of the company’s pricing policies.
After threats from Congress and a scolding from his own company, Valeant CEO Michael Pearson scheduled a deposition with a Senate committee investigating his company's price increases.